<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33314477</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Neck flexor weakness at diagnosis predicts respiratory impairment in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1181</StartPage><EndPage>1187</EndPage><MedlinePgn>1181-1187</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.14676</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">The purpose was to assess the prognostic role of neck muscle weakness at diagnosis in amyotrophic lateral sclerosis (ALS) patients with respect to survival and respiratory impairment.</AbstractText><AbstractText Label="METHODS">A retrospective cohort study was conducted. All ALS patients seen in the Turin ALS Centre from 2007 to 2014 were included. Muscle strength at diagnosis was evaluated using the Medical Research Council (MRC) scale. Survival was considered as the time from diagnosis to death or tracheostomy; time to respiratory impairment was considered as the interval from diagnosis to the first event amongst an ALS Functional Rating Scale revised item 10 &lt;4, forced vital capacity &lt;70%, start of non-invasive ventilation or tracheostomy. Time from diagnosis to dysarthria, dysphagia and walking impairment were considered as secondary outcomes. Cox proportional hazard regression models adjusted for sex, age at diagnosis, diagnostic delay, onset site, genetics status and the MRC scores of other muscle groups were used to assess the prognostic role of neck muscles.</AbstractText><AbstractText Label="RESULTS">A total of 370 patients were included in the study. Fifty-nine (15.9%) patients showed neck flexor weakness at diagnosis; MRC values were mostly in agreement for neck extensors. Neck flexors were the only muscles able to predict survival (hazard ratio 0.49, 95% confidence interval 0.28-0.86; p&#xa0;=&#xa0;0.01). Furthermore, neck flexor normal strength decreased the risk of respiratory impairment (hazard ratio 0.46, 95% confidence interval 0.22-0.96; p&#xa0;=&#xa0;0.04) but did not influence any secondary outcomes.</AbstractText><AbstractText Label="DISCUSSION">Neck flexor weakness at diagnosis predicts survival and respiratory impairment in ALS. This result could be valuable for both planning of patients' interventions and clinical trials' design.</AbstractText><CopyrightInformation>&#xa9; 2020 European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vasta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-0393-4736</Identifier><AffiliationInfo><Affiliation>ALS Centre, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torrieri</LastName><ForeName>Maria Claudia</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>ALS Centre, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Ovidio</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-6304-5415</Identifier><AffiliationInfo><Affiliation>ALS Centre, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Circiello</LastName><ForeName>Alberta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Mattei</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Centre, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>ALS Centre, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5876-4079</Identifier><AffiliationInfo><Affiliation>ALS Centre, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>ALS Centre, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology 1, AOU Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>12</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057210" MajorTopicYN="N">Delayed Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="Y">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">cohort studies</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">survival analysis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>14</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33314477</ArticleId><ArticleId IdType="doi">10.1111/ene.14676</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;5(3):17071.</Citation></Reference><Reference><Citation>Al-Chalabi A, Hardiman O, Kiernan MC, Chi&#xf2; A, Rix-Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol. 2016;15(11):1182-1194.</Citation></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5-6):310-323.</Citation></Reference><Reference><Citation>Calvo A, Vasta R, Moglia C, et al. Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. J Neurol. 2020;267(6):1615-1621.</Citation></Reference><Reference><Citation>Moglia C, Calvo A, Grassano M, et al. Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort. J Neurol Neurosurg Psychiatry. 2019;90(6):666-673.</Citation></Reference><Reference><Citation>Calvo A, Canosa A, Bertuzzo D, et al. Influence of cigarette smoking on ALS outcome: a population-based study. J Neurol Neurosurg Psychiatr. 2016;87(11):1229-1233.</Citation></Reference><Reference><Citation>Westeneng H-J, Debray TPA, Visser AE, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423-433.</Citation></Reference><Reference><Citation>Taylor AA, Fournier C, Polak M, et al. Predicting disease progression in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2016;3(11):866-875.</Citation></Reference><Reference><Citation>Ong M-L, Tan PF, Holbrook JD. Predicting functional decline and survival in amyotrophic lateral sclerosis. PLoS One. 2017;12(4):e0174925.</Citation></Reference><Reference><Citation>Nakamura R, Atsuta N, Watanabe H, et al. Neck weakness is a potent prognostic factor in sporadic amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2013;84(12):1365-1371.</Citation></Reference><Reference><Citation>Pinto S, de Carvalho M. Motor responses of the sternocleidomastoid muscle in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2008;38(4):1312-1317.</Citation></Reference><Reference><Citation>Yu C-J, Wang L, Mao S-L, et al. The clinical assessment of amyotrophic lateral sclerosis patients&#x2019; prognosis by ZNF512B gene, neck flexor muscle power score and body mass index (BMI). BMC Neurol. 2018;18(1):211.</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-299.</Citation></Reference><Reference><Citation>Chi&#xf2; A, Calvo A, Moglia C, Mazzini L, Mora G, PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatr. 2011;82(7):740-746.</Citation></Reference><Reference><Citation>Medical Research Council. Aids to the Examination of the Peripheral Nervous System, 4th edn. London: W.B.Saunders; 2000.</Citation></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1-2):13-21.</Citation></Reference><Reference><Citation>EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)-revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360-375.</Citation></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268.</Citation></Reference><Reference><Citation>Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol. 1996;49(8):907-916.</Citation></Reference><Reference><Citation>R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing [Internet]; 2013. Available from: http://www.R-project.org/</Citation></Reference><Reference><Citation>Drain JP, Virk SS, Jain N, Yu E. Dropped head syndrome: a systematic review. Clin Spine Surg. 2019;32(10):423-429.</Citation></Reference><Reference><Citation>Gourie-Devi M, Nalini A, Sandhya S. Early or late appearance of &#x201c;dropped head syndrome&#x201d; in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2003;74(5):683-686.</Citation></Reference><Reference><Citation>Augustine J. Human Neuroanatomy, 1st edn. Hoboken: Academic Press; 2006.</Citation></Reference><Reference><Citation>McAlary L, Plotkin SS, Yerbury JJ, Cashman NR. Prion-like propagation of protein misfolding and aggregation in amyotrophic lateral sclerosis. Front Mol Neurosci. 2019;12:262.</Citation></Reference><Reference><Citation>Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009;73(10):805-811.</Citation></Reference><Reference><Citation>Pinto S, de Carvalho M. The R of ALSFRS-R: does it really mirror functional respiratory involvement in amyotrophic lateral sclerosis? Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1-2):120-123.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>